Summary by Futu AI
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.